



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/70, 37/02, 39/305 C07K 7/08, C12N 15/00	A1	(11) International Publication Number: WO 92/18135 (43) International Publication Date: 29 October 1992 (29.10.92)
(21) International Application Number: PCT/US92/03065 (22) International Filing Date: 14 April 1992 (14.04.92) (30) Priority data: 686,342 15 April 1991 (15.04.91) US (60) Parent Application or Grant (63) Related by Continuation US 686,342 (CIP) Filed on 15 April 1991 (15.04.91) (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, 22nd Floor, Oakland, CA 94612 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : BEDNARSKI, Mark, D. [US/US]; 637 Alvarado Street, Berkeley, CA 94720 (US); BERTOZZI, Carolyn, R. [US/US]; 1040 Evelyn Avenue, #2, Albany, CA 94706 (US); NAGY, Jon, O. [US/US]; 120 Bonita Court, Rodeo, CA 94572 (US). (74) Agent: HESLIN, James, M.; Townsend and Townsend, One Market Plaza - 2000 Steuart Tower, San Francisco, CA 94105 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: COMPOSITIONS AND METHODS FOR INTRODUCING EFFECTORS TO PATHOGENS AND CELLS (57) Abstract <p>Compositions and methods for the inhibition and prevention of pathogenic infection and neoplastic disease are provided. The compositions include hybrid molecules having a binding moiety and an effector moiety joined by a linker region. When administered to a host, the binding moiety, such as a carbohydrate, attaches to a receptor, such as a conserved lectin receptor on the pathogen or neoplastic cell, and the effector moiety provides an invariant antigenic determinant for eliciting or modulating an immune response. The effector moiety may also be a drug or other compound which inhibits growth of a bound pathogen or cell. Compositions comprising the hybrid molecule in a suitable pharmaceutical carrier are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

**COMPOSITIONS AND METHODS FOR
INTRODUCING EFFECTORS TO PATHOGENS AND CELLS**

This invention was made with Government support under Grant (or Contract) No. NIH 1946002123A1, awarded by the Department of Health and Human Services. The Government has certain rights in this invention.

The present application is a continuation-in-part of application serial number 07/686,342, filed on April 15, 1991, the full disclosure of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to compositions and methods for specifically targeting pathogens and cells. More particularly, the present invention relates to the use of hybrid molecules including a receptor-binding moiety and an effector moiety for altering the antigenic character of or delivering drugs to pathogens and cells.

The primary defense mechanism of man and other vertebrates against pathogenic infection is the immune system. The immune response includes two separate pathways to deal with invasion by a foreign substance. The first pathway, referred to as the "humoral response," relies on antibody molecules to bind directly to pathogen to trigger a series of events (the complement cascade or the binding of macrophages and other leukocytes) to eliminate the pathogen from the body. The second immune pathway, referred to as the "cellular response," relies on T-cell recognition of an antigenic region on the pathogen, again leading ultimately to elimination of the pathogen from the system. Both the humoral and cellular responses thus rely on antigenic recognition of the pathogen in order to kill the pathogen and protect the host.

While the immune response is an exquisite and effective protective mechanism against a wide variety of pathogens, there are certain pathogens which evade both pathways of the immune response by changing their cell surface antigens sufficiently rapidly so that they are not recognized by the antibodies which have been elicited during earlier stages of infection. Pathogens with such an ability to evade the immune response include viruses, such as the influenza virus, papilloma viruses, picornaviruses, polyoma virus, and rhinoviruses; bacteria, such as *Escherichia coli* and *Vibrio cholerae*; and protozoa, such as *Entamoeba histolytica*, *Trypanosoma cruzii*, *Plasmodium knowlesi*, *P. vivax* and the like.

Most or all pathogens initiate infection by binding to a surface ligand on the cell being infected. For example, the pathogen may possess a lectin receptor which is able to specifically bind to a carbohydrate ligand on the cell to be infected. To prevent infection, it has been proposed to inhibit initial attachment of the pathogen using drugs which block binding of the pathogen to the cells which are subject to infection. While such drugs can be effective, high dosages may be required to block all available binding receptors on the pathogen. Moreover, the drugs are passive and do not enhance the killing and elimination of the pathogen from the host. Another class of blocking agents include soluble polypeptide receptors, such as soluble CD4 used to inhibit binding of HIV-1 to T-cells. The use of soluble polypeptide receptors has not generally been successful, perhaps due to degradation of the polypeptides after they are administered to a patient.

Sialic acids, derivatives of *N*-acetylneuraminic acid (NeuAc), are carbohydrate groups found terminating cell-surface glycoproteins and glycolipids. Glycosides of NeuAc are often utilized by pathogens as an attachment point to cells prior to infection. The use of sialic acid analogs as drugs directed towards the

influenza virus has been proposed. The use of O-linked glycosides as potential viral inhibitors, however, is severely limited because of the presence of the neuraminidase enzyme on the virus. This enzyme cleaves the glycosidic bond of NeuAc giving rise to the free sugar which does not inhibit viral attachment. Therefore, a stable non-hydrolyzable analog of sialic acid promises to be useful as an antiviral drug.

For these reasons, it would be desirable to provide improved compositions and methods for enhancing a host's immune response against pathogenic infection, particularly against pathogenic infection by organisms capable of altering their antigenic appearance over time. It would be particularly desirable to provide compositions which are able to target a pathogen and provide at least one invariant antigenic determinant so that a host's immune response can target the pathogen based on the invariant determinant. The compositions will desirably be small, preferably being less than 3 kilodaltons (kD), more preferably being less than 2 kD, and most preferably being less than 1 kD in order to increase their survival time after administration to the host. The compositions should further be substantially free from non-specific binding so that they target the immune response solely against the desired pathogenic organism. The compositions will preferably not themselves be destroyed by the immune response so that individual molecules may successively bind more than one pathogen to reduce the dosage required. It will further be desirable to administer compositions which elicit a secondary or memory response against an antigen against which the host has been previously sensitized.

2. Description of the Background Art

Soluble hybrid molecules, designated immunoadhesins, comprising the gp120-binding domain of CD4 glycoprotein attached to portions of the Fc region of IgG are described in Capon et al. (1989) Nature 337:525-

531. See also European Patent Application 0 314 317. Use of the immunoadhesins for treatment of acquired immunodeficiency syndrome (AIDS) is proposed. Hybrid receptors comprising the ligand-binding domain of a receptor, such as a growth factor receptor, attached to a heterologous reporter polypeptide, such as an enzyme are described in U.S. Patent No. 4,859,609, to Dull and Ullrich. Schultz and Shokat (1991) J. Am. Chem. Soc. 113:1861 describe the use of CD4-nitrophenol conjugates to target anti-DNP antibodies against HIV-1. Sharon and Lis (1989) Science 246:227-234 describe the nature of some pathogenic receptors (lectins) which bind to cell surface carbohydrates to initiate infection. Win compounds are described in Badger et al. (1988) Proc. Natl. Acad. Sci. 85:3304-3308. Win compounds bind to rhinoviruses and inhibit uncoating of virus (which is necessary for infection). The synthesis of sialic acid analogs intended for use as drugs is reported in Sauter et al. (1989) Biochemistry 28:8388 and Whitesides (1990) J. Am. Chem. Soc. 11:1000.

SUMMARY OF THE INVENTION

The present invention comprises a hybrid molecule which is able to bind to a receptor, usually a conserved receptor, on a pathogen or neoplastic cell in order to introduce at least one heterologous determinant site onto the pathogen or cell surface. The hybrid molecules are small molecules, typically having molecular weights below about 3 kD, which comprise a binding moiety attached to an effector moiety capable of eliciting or modulating an immune response when administered to a host. The binding moiety preferably binds to the pathogenic or cellular receptor with an affinity of at least about 1 mM^{-1} (10^{-3} M^{-1}). The binding moiety will typically mimic a carbohydrate binding region present on a host cell which binds the pathogen receptor as part of the initiation of infection or a neoplastic cell as part of the metastatic process. Usually, the binding moiety

will include at least one sugar characteristic of the host cell binding ligand (usually a terminal sugar) joined to the remainder of the hybrid molecule through a carbon-linkage. Such carbon-linked sugar(s) are desirable since they are less subject to chemical and enzymatic degradation, than are natural oxygen-linked sugars. Frequently, more than one sugar from the cell surface ligand will be incorporated in the hybrid molecule. Alternatively, other small drugs and moieties capable of binding to the receptor on the pathogen or neoplastic cells, other than carbohydrates, may be employed.

The effector moiety will usually be capable of eliciting, modulating, or otherwise participating in the humoral immune response when administered to a host as part of the hybrid molecule. In particular, the effector moiety may elicit a primary immunogenic response when the host has not been previously sensitized to the antigenic determinant defined by the effector. Alternatively, and preferably, the effector moiety may elicit a secondary or memory response when the host has previously been sensitized to the corresponding antigenic determinant. In addition or as a further alternative, the effector moiety may be a drug capable of killing a bound cell, inhibiting cellular attachment, or otherwise interfering with the pathogenic or metastatic process.

The linker will be capable of covalently binding to both the binding moiety and the effector moiety and will be able to maintain the proper spacing therebetween, typically from about 10Å to 40Å. The linker will usually be flexible to permit relative motion between the binding moiety and the effector moiety so that the effector moiety will be sufficiently exposed on the surface of the pathogen to participate in the desired interaction with the cells of the host's immune system. The linker should be substantially free from any features

which could result in non-specific binding of the hybrid molecules.

5 The present invention further comprises compositions containing the hybrid molecules as just described present in a pharmaceutically-acceptable carrier.

10 The present invention also comprises novel carbon-linked sialic acid derivatives which may be particularly useful in preparing the hybrid molecules described above.

15 The present invention provides methods for introducing a heterologous antigenic determinant to a pathogen or neoplastic cell by exposing the pathogen or cell to the hybrid molecules described above. The binding moiety of the hybrid molecules will specifically bind to the receptor, usually a conserved receptor, on the pathogen or cell, and the effector moiety provides an invariant determinant which can act as a target to elicit an immune response against the pathogen. The effector
20 may also provide for direct killing of the pathogen or cell. In a particular aspect, the method can be used to treat pathogenic infection by administering the hybrid molecule to a host to elicit or modulate the host's own humoral or cellular immune response.

25 BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1-4 illustrate the synthetic schemes for the preparation of carbon-linked mannose glycosides as described in the Experimental section hereinafter.

30 Fig. 5 is an electron micrograph showing the localization of gold particles on the surface of an *E. coli* cell. The particles were bound through a hybrid molecule consisting of a mannose binding moiety attached to biotin through a carbon linkage. Avidin, anti-avidin antibodies, and protein A labelled with the gold
35 particles were exposed to cell and completed a bridge binding the gold particles. The location of a gold particle is shown by the arrow.

Fig. 6 is an electron micrograph showing a strain of *E. coli*, similar to that illustrated in Fig. 5, in the absence of the hybrid molecule. The cell was exposed to avidin, anti-avidin antibodies, and protein A labelled with gold particles. No localization of the gold particles was achieved without the hybrid molecules.

Figs. 7-9 illustrate the synthetic scheme for the preparation of a carbon-linked sialic acid residue as described in the Experimental section hereinafter.

Fig. 10 is a graph illustrating the ability of biotinylated α -C-glycoside of mannose (BCM) to direct complement mediated killing of *E. coli* cells.

Fig. 11 is a graph illustrating the ability of α -methyl mannopyranoside to block binding of BCM and inhibit killing of *E. coli* cells.

Fig. 12 is a graph illustrating the ability of BCM-avidin-antibody complex to stimulate macrophage-mediated endocytosis.

Fig. 13 is a graph illustrating the ability of α -methyl mannopyranoside to block macrophage-mediated endocytosis.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

According to the present invention, hybrid molecules include a binding moiety and an effector moiety covalently joined together by a linker region. The binding moiety is capable of specifically binding to a conserved surface receptor, typically a lectin, on a pathogen of interest while the effector moiety is capable of eliciting or modulating an immune response when administered to a host. The linker is selected to maintain the effector molecule in a proper position relative to the pathogen to permit interaction with the host's immune system when the hybrid molecule is bound to the pathogen.

The hybrid molecules of the present invention are used to "immunologically target" a wide variety of human and animal pathogens including viruses, bacteria,

and protozoa. An exemplary list of pathogens which may be targeted is set forth in Table 1.

TABLE 1

	<u>Pathogen</u>	<u>Binding Sugar¹ or Other Moiety</u>
	VIRUSES:	
	Influenza Virus	NeuAc α 2 \rightarrow 6Gal
		NeuAc α 2 \rightarrow 3Gal
	Picornaviruses	Win compounds ²
10	Polyoma Virus	NeuAc α 2 \rightarrow 6Gal
	BACTERIA:	
	<i>Escherichia coli</i>	
	Type 1	Man(α -glycosides)
	Type P	Gal α 1 \rightarrow 4Gal
15	Type S	NeuAc α 2 \rightarrow 3Gal
	<i>Vibrio cholerae</i>	Gm ₃ (ganglioside)
	<i>Actinomyces</i>	Gal-X ³
	PROTOZOA:	
	<i>Entamoeba histolytica</i>	Gal β 1 \rightarrow 4GlcNAc
20	<i>Plasmodium knowlesi</i>	Duffy antigen
	<i>Plasmodium vivax</i>	Duffy antigen
	<i>Trypanosoma cruzi</i>	NeuAc ³

¹ NeuAc : N-acetylneuramic acid (sialic acid)
 25 Gal : Galactose
 GlcNAc : N-Acetylglucosamine
 Man : Mannose

² Win compounds are described in Badger et al. (1988),
 30 supra., the disclosure of which is incorporated
 herein by reference. These compounds specifically
 bind to a pocket within the viral protein VP1 β -
 barrel structure and are useful as binding moieties
 in the compositions of the present invention.

35 ³ Exact structure undetermined.

The target pathogen may be any pathogen which
 40 has a receptor, preferably a conserved receptor, which
 binds to a cell surface ligand as part of the initiation
 of infection within that cell. The pathogen receptors
 are usually lectins but may also be other molecules, such

as glycosidic enzymes, and the cell surface ligands are usually carbohydrates in the form of glycoproteins, glycolipids, oligosaccharides, and polysaccharides. Upon exposure to the pathogen, the binding moiety of the hybrid molecule will specifically attach to the pathogen receptor. The length and nature of the linker region permits the effector moiety to appear as an antigenic determinant of the pathogen itself. Thus, the pathogen will be processed by the host's immune system as if it naturally possessed the antigenic determinant defined by the effector moiety. The present invention is particularly useful for targeting pathogens having antigenic characteristics which vary over time, where the introduced antigenic determinant is invariant and can elicit or modulate a sustained immune response.

The hybrid molecules of the present invention will also be useful for binding and treating neoplastic cells based on binding of cell ligands to lectin receptors present on the neoplastic cells. Exemplary lectin receptors on neoplastic cells are responsible for binding to carbohydrate ligands on vascular endothelial cells, which is a necessary mechanism in the metastatic process. Thus, by employing binding moieties which mimic these cell-surface carbohydrate ligands, present on the endothelial cells, the hybrid molecules can specifically attach to the neoplastic cells. A number of exemplary carbohydrate ligands and corresponding neoplastic cell receptors are identified in Raz et al. (1987) Can. Met. Rev. 6:433-452, the disclosure of which is incorporated herein by reference. Specific extracellular matrix adhesion molecules are described in McCarthy et al. (1985) Can. Met. Rev. 4:125-152; the cell-cell CAM adhesion system is described in Brackenbury (1985) Can. Met. Rev. 4:41-58; and the lymphocyte homing receptor system is described in Stoolman (1989) Cell 56:907-910, the disclosures of which are incorporated herein by reference.

The binding moiety will be selected to specifically bind to a receptor, usually a conserved receptor, on the pathogen or neoplastic cell of interest. The moiety will typically have a molecular weight below about 2kD, usually being between about 2kD and 400 daltons, preferably being between about 1.5kD and 500 daltons, and will usually be other than a polypeptide or protein.

Most commonly, the binding moiety will be a carbohydrate comprising one or more sugars which are selected to mimic sugars, usually the terminal sugars, on the carbohydrate binding ligands on the cells infected by the pathogen (or attached by the neoplastic cell), usually being identical to the terminal residues which are bound during the infection or metastatic initiation process. Exemplary sugars include mannose, sialic acid, galactose, fucose, α -glucosamine, and derivatives thereof, usually linked through carbon rather than oxygen. Specific terminal sugars for a variety of pathogens are set forth in Table 1 above.

Other pathogens having such conserved carbohydrate ligands are described in the medical and scientific literature. See, for example, Cornfield et al., in *Sialic Acids*, Schauer, Ed., Springer-Verlag, New York, 1982. McGuire, in *Biological Roles of Sialic Acid*, Rosenberg and Schengrund, eds., plenum, New York, 1976; Sharon and Lis, *Lectins*, Chapman and Hall, London, 1989; and Mirelman, ed., *Microbial Lectins and Agglutinins: Properties and Biological Activity*, Wiley Series in Ecological and Applied Microbiology, Wiley-Interscience Publication, John Wiley and Sons, New York, 1986, the disclosures of which are incorporated herein by reference.

Carbohydrate binding moieties may be monovalent or multivalent and will usually comprise from one to eight sugars, more usually comprising from one to four sugars, and preferably comprising from one to two sugars,

with the individual sugars being joined by the glycosidic linkages which are present in the natural carbohydrate ligand, i.e., maintaining the same stereochemistry, preferably employing carbon linkages instead of the oxygen linkages. Methods for synthesizing such saccharides and oligosaccharides are well described in the chemical literature. See, for example, Paulsen and Tietz (1985) *Agnew. Chemie. Intl. Ed. Engl.* 24:128; Toone et al. (1987) *Tet. Lett.* 44:5365-5422; Palcic et al. (1989) *Carb. Res.* 190:1-11; Sabesin et al. (1986) *J. Am. Chem. Soc.* 108:2068-2080; and Schmidt (1986) *Agnew. Chemie. Intl. Ed. Engl.* 25:212, the disclosures of which are incorporated herein by reference. A particular method for synthesizing a carbon-linked sialic acid (NeuAc) is described in detail in the Experimental section hereinafter.

In addition to carbohydrate binding moieties as just described, the present invention may employ other small synthetic moieties that have a adequate binding affinity and specificity to the conserved receptors on the pathogen or neoplastic cells of interest. In particular, the binding moiety (carbohydrate and non-carbohydrate) should have a binding affinity to the pathogen or cellular receptor of at least about 1mM^{-1} (10^{-3}M^{-1}), preferably being at least about 0.01mM^{-1} (10^{-5}M^{-1}), and more preferably being at least about $1\mu\text{M}^{-1}$ (10^{-6}M^{-1}).

The non-carbohydrate binding moieties will usually be other than a protein or polypeptide. Exemplary non-carbohydrate binding moieties include the Win compounds described in Badger et al. (1988) *supra*.

The identification of other compounds that can be employed as the binding moiety, i.e., those which are capable of binding to the pathogen receptor with the requisite affinity, can be achieved through the use of techniques known to those working in the area of drug design. Such methods include, but are not limited to,

self-consistent field (SCF) analysis, configuration interaction (CI) analysis, and normal mode dynamics computer programs, all of which are readily available. See, Rein et al., *Computer-Assisted Modeling of Receptor-Ligand Interactions*, Alan Liss, New York, (1989).

Preparation of the identified compounds and moieties will depend on their structure and other characteristics and may normally be achieved by standard chemical synthesis techniques. See, for example, *Methods in Carbohydrate Chemistry*, Volumes I-VII: *Analysis and Preparation of Sugars*, Whistler et al., eds, Academic Press, Inc., Orlando, 1962, the disclosure of which are incorporated herein by reference.

The effector moiety will be selected to provide a desired response or recognition by the host's immune system (usually humoral) when the moiety becomes attached to the pathogen or neoplastic cell as a result of the hybrid molecule binding to a receptor associated with the pathogen or cell. The effector moiety itself will frequently be a small compound, typically having a molecular weight below about 1 kD, preferably below about 500 D, usually in the range from about 100 to 400 D, and more usually in the range from about 250 to 350 D. Thus, the effector moiety will often be haptenic rather than antigenic, i.e., it will be unable to induce a primary immune response by itself but will be immunogenic when combined with the remainder of the hybrid molecule. Even small (haptenic) molecules will, however, induce a secondary or memory response in hosts who have been previously sensitized to the particular antigenic determinant.

Under certain circumstances, it may be desirable to employ larger compounds as the effector moiety, typically having molecular weights above about 1 kD, sometimes having molecular weights above about 1.5 kD, and occasionally having molecular weights above about 2 kD. Such antigenic compounds will usually be

polypeptides or proteins, will usually be immunogenic by themselves (i.e., without binding to the remainder of the hybrid molecule) and may define more than one antigenic determinant site.

5 Antigenic determinants, sometimes referred to as epitopic sites or epitopes, are the portion of an antigenic or haptenic molecule that interacts with the host's immune system by molecular complementarity. In the humoral response, it reacts with cell surface Ig on
10 B-cells to induce antibody production.

 The antigenic determinant site(s) defined by the effector moiety will preferably be cross-reactive with an antigen or hapten to which the host has been previously sensitized. In this way, administration of
15 the hybrid molecule to the host will evoke a secondary or memory response which will have a substantially immediate effect on the target pathogen or neoplastic cells. Alternatively, the effector moiety may be selected to introduce an antigenic determinant to which the host has
20 not been previously exposed. In the latter case, the determinant will evoke a primary humoral response when administered to the host.

 Exemplary effector moieties include those capable of producing a strong immunogenic response when
25 administered to the host as part of the hybrid molecule, e.g., aminophenols, nitrophenols, fluorescent probes (fluroscein), phenolic glycosides (p-aminophenol- β -glycoside), and the like. Preferred effector moieties for which the host has a natural immunity include blood
30 group carbohydrates, e.g., α -D-GalNAc(1 \rightarrow 3) β -D-Gal, α -D-Galp-(1 \rightarrow 3)- β -D-Gal, α -D-GalpNAc-(1 \rightarrow 3)- β -D-Gal, and α -D-Galp-(1 \rightarrow 3)- β -D-Galp-(1 \rightarrow 3)- β -D-Gal; dinitrophenol (DNP); Gal α 1-3Gal; and the like.

 A particularly preferred effector moiety is the
35 Gal α 1-3Gal disaccharide for which most individuals have a natural immunity. The disaccharide and its properties are described in Galili et al. (1987) Proc. Natl. Acad.

Sci. USA 84:1369-1373; Galili et al. (1987) J. Biol. Chem. 262:4683-4688; and Galili et al. (1986) J. Clin. Invest. 77:27-33, the disclosures of which are incorporated herein by reference. The Gal α 1 \rightarrow 3Gal structure is preferred because it has been found that up to 1% of all circulating IgG in individuals is reactive with the disaccharide. The disaccharide can be prepared by chemical synthesis or by transfer of galactose using an appropriate glycosyltransferase to an acceptor molecule bearing a terminal galactosyl moiety. See, Larsen et al. (1989) Proc. Natl. Acad. Sci. USA 86:8227-8231, which describes a particular method for synthesizing the Gal α 1 \rightarrow 3Gal disaccharide, the disclosure of which is incorporated herein by reference.

The hybrid molecule compositions of the present invention may also employ commonly used and commercially available compounds as the effector moiety. The use of biotin and fluorescein effector moieties is described in detail in the Experimental section hereinafter.

While the effector moiety will most commonly provide for an invariant antigenic determinant, as described above, it is also possible that the effector moiety may be a drug or cytotoxic compound intended to kill or inhibit growth of the pathogen or neoplastic cell. Exemplary drugs and cytotoxic agents include antibacterial drugs; anti-neoplastic drugs; photoactivated compounds; radionuclides; toxin A chains, such as ricin A chain and abrin A chain; and the like.

While the hybrid molecule compounds of the present invention will find their greatest use in antigenic targeting of pathogens and neoplastic cells, they may also be used for the detection of pathogens or neoplastic cells in *in vitro* assays. The use of both biotin and fluorescein effector moieties is particularly convenient for *in vitro* assays as both biotin and fluorescein are well known reporter molecules for which a wide variety of detection systems exist.

The linking region or group is selected to provide the necessary covalent bridge between the binding moiety and the effector moiety. Frequently, the linking region will be derived from a bifunctional compound having a reactive group at one end which is capable of binding to the binding moiety and a second reactive group which is capable of binding to the effector moiety. Alternatively, the linking region may be synthesized together with either the binding moiety or the effector moiety and will then include only a single reactive functionality for covalent binding to the other moiety.

The nature of the linking region is not critical, but it should provide a sufficient spacing and flexibility between the binding moiety and the effector moiety so that the effector moiety is sufficiently exposed on the surface of the pathogen to interact with the host's immune system in a desired manner. The length of the linking region will usually be between about 10Å and 40Å, preferably being between about 15Å and 30Å. The linking region should be resistant to degradation when administered to a host as part of a hybrid molecule and should further not contribute to non-specific adhesion of the hybrid molecule, i.e., adhesion or binding to other than the target receptor. It will be appreciated that the hybrid molecules of the present invention should bind with a high affinity and specificity to only the pathogen of interest.

The carbohydrate binding moieties will preferably be attached to the other portions of the hybrid molecule through carbon bonds. While natural glycosidic linkages occur through an oxygen (O-glycosidic bonds), the hybrid molecules of the present invention preferably employ carbon-glycosidic bonds to promote stability and inhibit chemical and enzymatic hydrolysis. Specific syntheses techniques for preparing such C-linked glycosides are set forth in the Experimental section hereinafter.

Exemplary bifunctional compounds which can be used for attaching carbohydrate moieties to effector moieties include bifunctional polyethylene glycols, polyamides, polyethers, polyesters, and the like.

5 General approaches for linking carbohydrate moieties to other small molecules, polypeptides, and the like, are well described in the chemical literature. See, for example, Lee et al. (1989) *Biochemistry* 28:1856 (carbohydrate conjugation); Bhatia et al. (1989) *Anal.*
10 *Biochem.* 178:408 (protein conjugation); Janda et al. (1990) *J. Am. Chem. Soc.* 112:8886 (protein conjugation), the disclosures of which are incorporated herein by reference.

The hybrid molecules of the present invention
15 can be incorporated as components of pharmaceutical compositions useful to attenuate, inhibit, prevent, or otherwise treat pathogenic infections or neoplastic disease. The pharmaceutical compositions should contain a therapeutic or prophylactic amount of at least one
20 hybrid molecule according to the present invention present in a pharmaceutically-acceptable carrier. The pharmaceutically-acceptable carrier can be any compatible, non-toxic substance suitable to deliver the hybrid molecules to an intended host. Sterile water,
25 alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically-acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions. The preparation of pharmaceutical
30 compositions incorporating active agents is well described in the medical and scientific literature, see, for example, *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, PA, 16th Ed., 1982, the disclosure of which is incorporated herein by reference.

35 The pharmaceutical compositions just described are suitable for systemic administration to the host, including both parental and oral administration.

Preferably, the pharmaceutical compositions will be administered parenterally, i.e., subcutaneously, intramuscularly, or intravenously. Thus, the present invention provides compositions for administration to a host, where the compositions comprise a pharmaceutically-acceptable solution of the hybrid molecules in an acceptable carrier, as described above.

The concentration of the hybrid molecules in the pharmaceutical compositions may vary widely, i.e., from less than about 0.1% by weight of the pharmaceutical composition to about 20% by weight, or greater. A typical pharmaceutical composition for intramuscular injection would be made up to contain, for example, 1 to 4 ml of sterile buffered water and $1\mu\text{g}$ to 1 mg of the hybrid molecule in the present invention. A typical composition for intravenous infusion could be made up to contain 100 to 500 ml of sterile Ringer's solution and about 1 to 100 mg of the hybrid molecule.

The pharmaceutical compositions of the present invention can be administered for prophylactic and/or therapeutic treatment of pathogenic infection. In therapeutic applications, the pharmaceutical compositions are administered to a host already infected with the pathogen. The pharmaceutical compositions will be administered in an amount sufficient to bind to at least a substantial portion of the population of viable pathogens present in the host. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Such effective dose will depend on the severity of the infection and on the general state of the patient's own immune system, but will generally range from about $0.01\mu\text{g}$ to 10 mg of the hybrid molecule per kilogram of body weight of the host, with dosages of from about $0.1\mu\text{g}$ to 1 mg/kg being more commonly employed. In life-threatening situations, it may be desirable to administer dosages substantially exceeding those set forth above.

For prophylactic applications, the pharmaceutical compositions of the present invention are administered to a host not already infected by the pathogen, but perhaps recently exposed to or thought to have been exposed to, or at risk of being exposed to the pathogen. The hybrid molecules will then be able to block initial infection of the patient cells by the pathogen as well as being able to elicit an immune response directly against the pathogen which may be present. The amount of hybrid molecule required for this purpose, referred to as a prophylactically-effective dosage, are generally the same as described above for therapeutic treatment.

For the treatment of neoplastic disease, the pharmaceutical compositions may be formulated generally as described above. The dosages and frequency of administration will depend heavily on the stage of disease, the prognosis, evidence of metastasis, and the like. Frequently, treatment will be performed in combination with other modalities, such as surgery, radiation treatment, administration of other chemotherapeutic drugs, and the like.

The following examples are offered by way of illustration, not by way of limitation.

EXPERIMENTAL

C-glycosides were synthesized as outlined in Figs. 1-4. Methyl (2,3,4,6-tetra-O-benzyl)- α -D-mannopyranoside 1 was treated with allyltrimethylsilane in acetonitrile using trimethylsilyl triflate (TMSOTf) as a catalyst according to conditions reported by Hosomi et al. (1984) Tetrahedron Lett. 25:2383; Hosome et al. (1987) Carbohydrate Research 171:223 (Fig. 1). The C-glycosides 2 and 3 were obtained in a greater than 15:1 mixture in an overall yield of 91%. Compound 2 was deprotected and reduced by hydrogenolysis (H_2 , Pd/C) to give alkane 4 (Fig. 2.).










Compounds 6-8 were synthesized from alcohol 5 which was obtained by hydroboration (9-BBN) of compound 2. Oxidation of alcohol 5 using Jones' reagent (CrO_3 , H_2SO_4) followed by hydrogenolysis (H_2 , Pd/C) gave the free acid 6. The amine hydrochloride salt 7 was synthesized from compound 5 by mesylation of the primary alcohol (MsCl , Et_3N) followed by azide displacement (nBu_4NN_3 , CH_3CN) (Brandstrom et al. (1974) Acta Chem. Scand. B 28:699) and hydrogenolysis (H_2 , $\text{Pd}(\text{OH})_2$, HCl). Debenzylation (H_2 , Pd/C) of compound 5 directly gave alcohol 8. Reaction of compound 7 with N-hydroxysuccinimidobiotin and Et_3N in 1:1 DMF/MeOH gave conjugate 9 (Fig. 3).

It has been reported that β -O-glycosides of mannose do not bind to *E. coli* type 1 pili receptors (Firon et al. (1984) Infection and Immunity 43:1088). Therefore, as a control for the cell-surface binding studies, we synthesized by β -C-glycoside 3 using a modification of a procedure developed by Lewis et al. (Fig. 4) (Lewis et al. (1982) J. Am. Chem. Soc. 104:4976). The addition of allylmagnesium bromide to lactone 10 (Lactone 10 was synthesized from methyl (2,3,4,6-tetra-O-benzyl)- α -D-mannopyranoside by hydrolysis of the methyl glycoside (AcOH , H_2O) followed by Jones' oxidation ($\text{CrO}_3/\text{H}_2\text{SO}_4$) in acetone.) gave hemiketal 11 as a mixture of anomers. Stereoselective reduction using triethylsilane and boron trifluoride etherate (Et_3SiH , BF_3OEt_2) in acetonitrile gave a 1:10 mixture of C-glycosides 2 and 3. Compound 3 was deprotected and reduced by hydrogenolysis to give alkane 12.

Compounds 4, 6-9 and 12 were assayed for bacterial receptor binding using agglutination studies with yeast cells and their inhibitory activity was compared to that of methyl α -D-mannopyranoside 13 (Firon et al. (1983) Carbohydrate Research 120:235; Eshdat et al. (1978) Biochem. Biophys. Res. Commun. 85:1551; and Firon et al. (1982) Biochem. Biophys. Res. Commun.

105:1426. The bacterial strain used in our study was a systemically invasive *E. coli* K1 *pilA+::tetR* strain that is responsible for sepsis and meningitis in human infants (Bloch et al. (1990) *Infection and Immunity* 58:275). A summary of the results is given in Table 2.

Table 2: Inhibitory Activity of C-Glycosides of Mannose on the Bacterial Receptor-Mediated Agglutination of Yeast Cells.^a

Entry	Compound	Concentration (mM) ^b	Relative Inhibitory Activity ^c
1		67	1
2		47	1.4
3		40	1.7
4		13	5.2
5		7	9.6
6		7	9.6
7		1.6	42
8	 + Streptavidin	0.6 mM ^d	---
9	 + Avidin	0.05 mM (50 μ M)	1340

- ^a *E. coli* K1 *pilA+::tetR* were grown for 24 h at 37°C on solid LB media supplemented with tetracycline and were suspended with a cotton swab in 4 mL of Dulbecco's PBS to a final dilution of 2×10^8 cells/mL. Yeast (*Saccharomyces cerevisiae*, wild type) were grown for 36 h on solid YPD media at 30°C and were suspended with a cotton swab in 4 mL of Dulbecco's PBS to a final dilution of 1×10^8 cells/mL. Protein concentrations were determined by BCA Protein Assay (Pierce). Agglutination assays were performed on a 20 well ceramic ring plate. Typically, 90 μ l of a solution of the test compound was combined with 30 μ l of the bacterial suspension. After 30 seconds, 30 μ l of the yeast suspension was added to give a final volume of 150 μ l and the wells were allowed to develop for 3 min. with agitation. A 5 μ l aliquot was removed from each well and spread onto a standard microscope slide. The slides were quickly heat fixed and mounted with 10 μ l of glycerol. The slides were examined under phase contrast at 500x magnification using a Zeiss Axioskop microscope. Agglutination was observed as clusters of cells. total inhibition of agglutination was determined by the observation of single cells only.
- ^b Concentration causing total inhibition of yeast agglutination.
- ^c These numbers represent the concentration of methyl α -D-mannopyranoside divided by the concentrations listed in column 3.
- ^d Only partial inhibition of agglutination was achieved at this concentration.

Three important conclusions can be drawn from these data: (1) Carbon-linked glycosides bind to bacterial mannose lectins and inhibit the attachment of *E. coli* K1 cells to yeast. Since the 28kD lectin is highly conserved in its morphology as determined by its cross reactivity with monoclonal and polyclonal antibodies (Hanson et al. (1988) Nature 332:265), these compounds should also bind to other type 1 pili receptors. The β -C-glycoside 12 shows no inhibitory activity at a concentration of 100 mM, demonstrating that the α -specificity of the receptor observed with O-glycosides is maintained among C-glycosides. (2) The binding of C-glycosides is stronger than that of methyl α -D-mannopyranoside 13. The increase in binding affinity seems to be a function of the hydrophobicity of the

carbon-linked side chain. For example, compare the charged compounds 6 and 7 (entries 2 and 3) with the neutral, hydrophobic compounds 4 and 9 (entries 5 and 6). Compounds 4 and 9 inhibit agglutination at a concentration that is approximately one order of magnitude less than that of the charged compounds 6 and 7. It is believed that the poor solvation of the hydrophobic side chain in water increases the affinity of compounds 4 and 9 for the relatively hydrophobic receptor binding site. This "hydrophobic effect" has also been observed with oxygen-linked glycosides such as compound 14 (entry 7) (Firon et al. (1982) *supra.*).

Finally, it was observed an increase in binding affinity for the biotin-streptavidin (avidin) system (entries 8 and 9, Table 2). Unfortunately, streptavidin has limited solubility under the conditions of the assay. Despite the apparent increase in affinity of the conjugate of streptavidin and compound 9, total inhibition was not achieved at this concentration (entry 8). Avidin, a more soluble protein, was therefore used in place of streptavidin. It was observed that avidin alone has an intrinsic affinity for the receptor binding site which is probably due to its glycosylation pattern (total inhibition of agglutination by avidin is achieved at a concentration of 0.4 mM (Huang et al. (1971) *J. Biol. Chem.* 246:686)). However, the conjugate of avidin with compound 9 (entry 9) inhibits agglutination at a concentration of 0.05 mM (50 μ M), an order of magnitude less than avidin alone, and was the tightest binding C-glycoside conjugate in our study. This effect was believed to be due to the tetravalency of the biotin-avidin complex. Biotinylation of ligands that bind to cell-surface receptors can be used as a general approach to create multivalent ligand arrays with control over their spacial arrangement.

The biotin-avidin system also allowed targeting molecules to the surface of pathogenic organisms. Since

the binding of the conjugate alters the antigenic properties of the bacterial surface, the strategy can be used to target anti-avidin antibodies to the pathogen that would not otherwise recognize the organism.

5 *E. coli* cells bound with avidin, as described above, were sequentially exposed to anti-avidin antibodies and gold (15 nm) colloidal particles bound to protein A. It was expected that the gold would localize on the *E. coli* cell surface through an antibody-protein A
10 bridge. Localization on bacterial pili was confirmed by transmission electron microscopy (TEM). The results are shown in Fig. 5 (typical gold particle shown by arrow) and Fig. 6 (control where *E. coli* cells incubated with protein A-gold without anti-avidin antibody).

15 Binding of complement (C1q) to anti-avidin (IgG2) bound to *E. coli* through the biotin-mannose hybrid molecule has also been shown. C1q binding is the first step in the complement cascade which is part of the humoral response.

20 A stable non-hydrolyzable analog of sialic acid 13 (Fig. 7) was synthesized as follows. The compound is a carbon glycoside of NeuAc prepared by a combined chemical enzymatic approach.

 Several methods for the synthesis of carbon
25 glycoside (C-glycosides) have been reported. See, Crich and Lim, (1990) Tet. Lett. 31:1897; Nicotra et al. (1987) J. Org. Chem. 52:5627; Hosomi et al. (1984) Tet. Lett. 25:2383; and Norbeck et al. (1987) J. Org. Chem. 52:2174. In our hands, many of these methods failed to give C-
30 glycosides of *N*-acetyl neuraminic acid under a variety of conditions. Problems associated with Lewis-acid catalyzed methods exist due to the carboxylate. Approaches that require basic conditions fail because of a variety of unwanted side reactions. The use of radical
35 coupling reactions eliminates these problems.

 The key radical species required for C-glycoside synthesis is generated under mild conditions

and on a carbon atom that can be stabilized by the adjacent carboxylate group and oxygen atom attached to it (capadative radical). Schmidt et al., for example, has shown that methyl-2-deoxy-2- β -chloro-4,7,8,9-tetra-O-acetyl-N-acetyl-neuraminate can readily be reduced using tributyl tin hydride (Schmidt et al. (1988) Tet. Lett. 29:3643. Towards this end the ethyl ester of neuraminic acid (Compound 4) was synthesized by an enzyme catalyzed aldol reaction using NeuAc aldolase between N-acetyl mannosamine (Hosomi et al. (1984) Tet. Lett. 25:2382) and sodium pyruvate to give NeuAc 3 (Bednarski et al. (1988) J. Amer. Chem. Soc. 110:7159; Auge et al. (1984) Tet. Lett. 25:4663; and Kim et al. (1988)). Treatment of the crude reaction mixture with hydrogen chloride gas in ethanol gives the ethyl ester which can be purified by silica gel chromatography. The data for this compound has been reported in Eschenfelder and Brossmer (1975), Tet. Lett. 35:3069. Treatment of compound (Norbeck et al. (1987) J. Org. Chem. 52:2174) with acetyl chloride at room temperature for 24 h gives the glycosyl chloride 16.

Compound 17 was then treated with allyl tributyltin and a catalytic amount of bis (tributyltin) and photolyzed for 18 h using a 450 watt Hanovia lamp with a pyrex filter to give approximately a 1:1 mixture of the C-glycosides 18 and 19 which were deprotected using sodium ethoxide in aqueous ethanol yielding 19 and 20 which could easily be separated by silica gel chromatography. Compound 19 (the less polar isomer) is assigned to be the α -anomer in which the carboxylate group is axial; compound 20 (the more polar isomer) is assigned to be the β -anomer. The stereochemical assignment is based on analogous compounds and NOE studies.

The following experiments demonstrate that biotinylated α -C-glycoside of mannose (BCM; Compound 6 in Table 2, above) is able to activate complement in an assay system employing *E. coli* K-12 HB101 cells

containing a plasmid (pSH2) that confers type 1 piliation (Orndorff et al. (1984) J. Bacteriol. 160:61-66). The cells were incubated with the BCM-avidin-antibody complex and treated with 10% guinea pig complement. The surviving cells were counted as colonies on solid media. It was found that the BCM-avidin-antibody complex activates complement at the surface of the bacterial cells resulting in cell death (Fig. 10). Increasing the concentration of the BCM-avidin-antibody complex also led to increased cell killing. Control experiments in which either the BCM-avidin conjugate or the anti-avidin antibodies were omitted show no significant cell death. When the same experiments were performed on non-piliated *E. coli* K-12 HB101 cells, no significant cell death was observed (data not shown). Furthermore, the bactericidal effect of the BCM-avidin-antibody complex was reversed in the presence of increasing concentrations of α -methyl mannopyranoside (Fig. 11). This compound binds to the bacterial receptors and prevents an otherwise lethal amount of the BCM-avidin-antibody complex from coating the cells. The same protective effect was not observed in the presence of α -methyl glucopyranoside, which does not bind to the receptors. The BCM-avidin-antibody complex can therefore specifically bind to the cell-surface receptors and activate complement for cell killing.

Data presented in Fig. 10 were obtained as follows. Bacteria were incubated with the BCM-avidin-antibody complex (\square) followed by 10% guinea pig complement. Increased amounts of the BCM-avidin-antibody complex results in increased cell death. Control experiments containing only anti-avidin antibodies (no BCM-avidin) (Δ) or BCM-avidin (no anti-avidin antibodies) (\bullet) showed no significant cell death. The concentration of antibodies is four times that of BCM-avidin for each data point.

Data presented in Fig. 11 were obtained as follows. Bacteria were incubated with the BCM-avidin-antibody complex (6.0×10^{-7} M in BCM-avidin and 24×10^{-7} M in IgG) in the presence of increasing amounts of α -methyl mannopyranoside (■) or α -methyl glucopyranoside (Δ) and treated with 10% guinea pig complement. Mannose inhibits cell killing (■) while glucose has no protective effect (Δ). *E. coli* K-12 HB101 (pSH2) were grown for 24 hours in static LB broth supplemented with chloramphenicol and washed once with PBS before use. The cells were tested for piliation by agglutination experiments with yeast cells (Clegg et al. (1987) J. Bacteriol. 169:934-938) and by colony morphology (Orndorff et al. (1984) *supra*). The conjugate of BCM with avidin was formed by incubating a ten-fold excess of BCM with egg-white avidin (Sigma) overnight at 0°C. The solution was then dialyzed against PBS (3 x 400 mL, 6,000-8,000 MW cutoff) and the total protein concentration determined by BCA protein assay (Pierce) and $E^{1\%}_{280}$. The BCM-avidin-antibody complex was formed by incubating BCM-avidin with a four-fold excess of monoclonal anti-avidin IgG1k (Sigma) overnight at 0°C. In a typical experiment, 10^7 *E. coli* cells were incubated with the BCM-avidin-antibody complex and guinea pig complement (10% v/v, Calbiochem) for 2 hours at 37°C. The suspension was diluted 1,000-fold with PBS and 25 μ L of the resulting suspension was plated in triplicate on solid LB media supplemented with chloramphenicol. The plates were developed overnight at 37°C and the surviving cells were counted as colonies. Data points represent average values for three plates and error bars represent the standard deviation of the mean. Similar results were obtained for duplicate experiments.

The capability of the BCM-avidin-antibody complex to stimulate macrophage-mediated endocytosis was also investigated. Macrophage-mediated killing of the

BCM-avidin-antibody coated bacterial cells was assayed using a macrophage-monocyte related cell line (J774) that kills antibody-coated cells predominantly by Fc receptor-mediated endocytosis (Ralph et al. (1975) Nature 257:393-394). *E. coli* cells were incubated with the BCM-avidin-antibody complex and treated with macrophage cells in an effector-target ratio of 1:2. Bacterial cell killing was determined by counting survivors on solid media. It was found that the BCM-avidin-antibody complex stimulates macrophage-mediated killing when bound to the bacterial cell surface (Fig. 12). Increasing concentrations of the BCM-avidin-antibody complex resulted in a significant increase in cell death. Both the BCM-avidin conjugate and the anti-avidin antibodies had no bactericidal activity alone. Furthermore, macrophage-mediated killing was inhibited in the presence of α -methyl mannopyranoside and not by α -methyl glycopyranoside (Fig. 13) similar to the results obtained using complement proteins. It is interesting to note that unlike the complement experiments (Figs. 10 and 11), total cell killing by macrophage cells was not obtainable even at concentrations of the BCM-avidin-antibody complex up to 1 μ M (only about 75% killing was observed at this concentration). It is possible that at higher concentrations of BCM-avidin-antibody complex, the antibody clusters in solution effectively compete for Fc receptor sites thus preventing the Fc receptors from binding to antibodies localized on the bacterial cell. A similar effect has been seen with antibody coated erythrocytes (Ralph et al. (1975) *supra*).

These results demonstrate that antibodies directed to the surface of the bacterial cells through the interaction of the BCM-avidin conjugate with the mannose receptors are capable of activating both complement proteins and macrophages for cell killing. Similar bifunctional glycoconjugates may be used as a

general strategy to target antibodies to pathogens that would otherwise not recognize the organism.

Data presented in Fig. 12 were obtained as follows. Bacterial cells were incubated with the BCM-
5 avidin-antibody complex (■) followed by macrophage cells. Increased cell death is observed with increased concentrations of the BCM-avidin-antibody complex. Control experiments in which either anti-avidin
10 antibodies (Δ) or BCM-avidin (●) were incubated with bacterial cells followed by complement show no change in the amount of cell death. The concentration of antibodies is four times that of BCM-avidin for each data point.

Data presented in Fig. 13 were obtained as follows. α-Methyl mannopyranoside (■) inhibits the
15 bactericidal activity of the BCM-avidin-antibody complex (6.0×10^{-7} M in BCM-avidin and 24×10^{-7} M in IgG). Unlike α-methyl mannopyranoside, the α-methyl glycoside of glucose (Δ) has no inhibitory effect. Macrophage J774
20 cells (ATCC) were grown in DME media supplemented with 10% heat inactivated fetal calf serum. Cells were harvested, washed twice with 45 mL of PBS and resuspended as previously described. In a typical experiment, 10^6 bacterial cells were treated with the BCM-avidin-antibody
25 complex followed by 5×10^5 macrophage cells. The suspension was incubated at 37°C for 3 hours. After a 100-fold dilution with PBS, 25 μL of the resulting suspension was plated in triplicate. Survivors were
30 counted as previously described in Fig. 2. Data points represent average values for three plates and error bars represent the standard deviation of the mean.

Detailed synthesis methods for each of the compounds described in the Experimental section are contained in the Appendix to this application.

Although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims.

5

WHAT IS CLAIMED IS:

1. A hybrid molecule having a molecular weight below 3 kD and comprising a binding moiety attached to an effector moiety by a linker region, wherein the binding moiety is capable of specifically binding to a pathogen or cellular receptor, the effector moiety is capable of eliciting an immune response or inhibiting growth of a bound pathogen or cell when administered to a host, and the linker region is water soluble and substantially free from non-specific cellular binding.
2. A hybrid molecule as in claim 1, having a molecular weight below about 2 kD.
3. A hybrid molecule as in claim 1, wherein the binding moiety is a carbohydrate.
4. A hybrid molecule as in claim 1, wherein the binding moiety will bind to the pathogen receptor with an affinity of at least about 1 mM^{-1} .
5. A hybrid molecule as in claim 3, wherein the carbohydrate moiety terminates in at least one carbon-linked sugar.
6. A hybrid molecule as in claim 5, wherein the carbon-linked sugar is selected from the group consisting of mannose, sialic acid, galactose, fucose, α -glucoseamine, galactosamine, and derivatives thereof.
7. A hybrid molecule as in claim 1, wherein the effector moiety has a molecular weight below about 1000 D.
8. A hybrid molecule as in claim 1, wherein the effector moiety is selected from the group consisting

of blood group carbohydrates, dinitrophenol, and Gal α 1 \rightarrow 3Gal.

5 9. A hybrid molecule as in claim 1, wherein the binding moiety is sialic acid and the effector moiety is Gal α 1 \rightarrow 3Gal.

10 10. A hybrid molecule as in claim 1, wherein the linking region has a length in the range from 10Å to 40Å.

15 11. A method for introducing a heterologous antigenic determinant to the surface of a pathogen or cell, said method comprising exposing the pathogen or cell to hybrid molecules having a binding moiety capable of specifically binding to a conserved pathogen or cellular receptor and an effector moiety which presents the heterologous antigenic determinant when the binding moiety is bound to the receptor.

20 12. A method as in claim 11, wherein the hybrid molecule has a molecular weight below about 3 kD.

25 13. A method as in claim 11, wherein the binding moiety is a carbohydrate which terminates in at least one carbon-linked sugar.

30 14. A method as in claim 13, wherein the carbon-linked sugar is selected from the group consisting of mannose, sialic acid, galactose, fucose, α -glucoseamine, galactosamine, and derivatives thereof.

35 15. A method as in claim 13, wherein the receptor is a conserved pathogen receptor which mediates attachment of the pathogen to susceptible cells.

16. A method as in claim 11, wherein the receptor is a conserved cellular receptor which mediates metastatic attachment of a neoplastic cell.

5 17. A method as in claim 11, wherein the pathogen is a viral pathogen selected from the group consisting of influenza viruses, picornaviruses, and papilloma viruses.

10 18. A method as in claim 11, wherein the pathogen is a bacteria selected from the group consisting of *Escherichia coli*, and *Vibrio cholerae*.

15 19. A method as in claim 11, wherein the pathogen is a protozoa selected from the group consisting of *Entamoeba histolytica*, *Plasmodium knowlesi*, *Plasmodium vivax*, and *Trypanosoma cruzii*.

20 20. A method for treating a host infected by a pathogen, said method comprising:

administering to the host a hybrid molecule having a binding moiety which specifically binds to a conserved receptor on the pathogen and an effector moiety which modulates the host's immune response or inhibits pathogen growth, wherein the hybrid molecule has a
25 molecular weight below 3 kD.

30 21. A method as in claim 20, wherein the conserved receptor is a lectin receptor which mediates attachment of the pathogen to a cell to be infected.

22. A method as in claim 21, wherein the binding moiety is a carbohydrate having at least one carbon-linked sugar.

35 23. A method as in claim 22, wherein the carbon-linked sugar is selected from the group consisting

of mannose, sialic acid, galactose, fucose,
 α -glucoseamine, galactosamine, and derivatives thereof.

5 24. A method as in claim 20, wherein the
effector moiety is selected from the group consisting of
blood group carbphyrates, dinitrophenol, and Gal α 1-3Gal.

10 25. A method as in claim 20, wherein the
pathogen is a viral pathogen selected from the group
consisting of influenza viruses, picornaviruses, and
papilloma viruses.

15 26. A method as in claim 20, wherein the
pathogen is a bacteria selected from the group consisting
of *Escherichia coli*, and *Vibrio cholerae*.

20 27. A method as in claim 20, wherein the
pathogen is a protozoa selected from the group consisting
of *Entamoeba histolytica*, trypanosomes, *Plasmodium*
knowlesi, *Plasmodium vivax*, and *Trypanosoma cruzii*.

25 28. A method for treating a host having a
neoplastic disease, said method comprising:
administering to the host a hybrid molecule
having a binding moiety which specifically binds to a
conserved receptor on neoplastic cells and an effector
moiety which modulates the host's immune response or
inhibits cell growth, wherein the hybrid molecule has a
molecular weight below 3 kD.

30

29. A method as in claim 28, wherein the
conserved receptor is a lectin which mediates metastatic
cellular attachment.

35 30. A method as in claim 29, wherein the
binding moiety is a carbohydrate having at least one
carbon-linked sugar.

31. A method as in claim 30, wherein the carbon-linked sugar is selected from the group consisting of mannose, sialic acid, galactose, fucose, α -glucoseamine, galactosamine, and derivatives thereof.

5

32. A method as in claim 28, wherein the effector moiety is selected from the group consisting of blood group carbohydrates, dinitrophenol, and Gal α 1 \rightarrow 3Gal.

10

33. A method as in claim 28, wherein the pathogen is a viral pathogen selected from the group consisting of influenza viruses, picornaviruses, and papilloma viruses.

15

34. A method as in claim 28, wherein the pathogen is a bacteria selected from the group consisting of *Escherichia coli*, and *Vibrio cholerae*.

20

35. A method as in claim 28, wherein the pathogen is a protozoa selected from the group consisting of *Entamoeba histolytica*, trypanosomes, *Plasmodium knowlesi*, *Plasmodium vivax*, and *Trypanosoma cruzii*.

25

36. Compositions comprising the hybrid molecule of claim 1, present in a pharmaceutically-acceptable carrier.

37. Carbon-linked sialic acid.




FIG. 1.




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.

SUBSTITUTE SHEET




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.






FIG. 11

**FIG. 12.****FIG. 13.**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03065

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 31/70, 37/02, 39/395; C07K 7/08; C12N 15/00

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450; 435/7.2, 7.22, 7.32, 7.37; 514/23, 53, 54, 61, 63, 837, 888; 536/4.1, 17.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	US, A, 4,844,893 (Honsik et al) 04 July 1989, see entire document.	11-19 1-10 & 20-36
A	US, A, 4,207,414 (Kasper) 10 June 1980, see entire document.	37
A	US, A, 4,476,119 (della Valle et al) 09 October 1984, see entire document.	1-10 & 20-36
A	US, A, 4,965,198 (Yamazaki et al) 23 October 1990, see entire document.	1-10 & 20-36
A	US, A, 4,698,420 (Urnovitz) 06 October 1987, see entire document.	1-10 & 20-36
A	US, A, 4,694,076 (Ogawa et al) 15 September 1987, see entire document.	37
A	US, A, 4,845,026 (Kung et al) 04 July 1989, see entire document.	1-10 & 20-36
A	US, A, 4,869,826 (Wang et al) 26 September 1989, see entire document.	1-10 & 20-36
A	US, A, 4,914,035 (Hasegawa et al) 03 April 1990, see entire document.	37

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 JULY 1992

Date of mailing of the international search report

28 JUL 1992

Name and mailing address of the ISA/
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer:

RONALD W. GRIFFIN

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03065

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF ORGANIC CHEMISTRY, Volume 52, issued 1987, D.W. Norbeck et al, "Synthesis of an Isosteric Phosphonate Analogue of Cytidine 5'-Monophospho-3-deoxy-D-manno-2-octulosonic Acid", pages 2174-2179.	11-19
A	Tetrahedron Letters, Vol 25, no 22, issued 1984, Hosami et al, "HIGHLY STEREOSELECTIVE C ALLYLATION...IODOSILANE", pages 2383-2386.	11-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/03065

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,918,177 (Yoshimura et al) 17 April 1990, see entire document.	37
A	US, A, 4,925,796 (Bergh et al) 15 May 1990, see entire document.	37
A	US, A, 4,963,653 (Nagai et al) 16 October 1990, see entire document.	37
A	US, A, 4,990,603 (Ogawa et al) 05 February 1991, see entire document.	37
A	US, A, 3,951,748 (Devlin) 20 April 1976, see entire document.	11-19
A	US, A, 4,297,104 (Claude) 27 October 1981, see entire document.	11-19
A	US, A, 4,693,966 (Houghton et al) 15 September 1987, see entire document.	11-19
A	US, A, 4,886,743 (Hood et al) 12 December 1989, see entire document.	11-19
A	US, A, 4,981,782 (Judd et al) 01 January 1991, see entire document.	11-19
A,P	US, A, 5,019,387 (Haynes et al) 28 May 1991, see entire document.	11-19
A,P	US, A, 5,030,565 (Niman et al) 09 July 1991, see entire document.	11-19
A,P	US, A, 5,064,755 (Howard et al) 12 November 1991, see entire document.	11-19
A	US, A, 4,859,609 (Dull et al) 22 August 1989, see entire document.	11-19
A	EP, A, 0,314,317 (Capon et al) 03 May 1989, see entire document.	11-19
A	NATURE, Volume 337, issued 09 February 1989, (LONDON, GB), D.J. Capon et al, "Designing CD4 immunoadhesins for AIDS therapy", pages 525-531.	11-19
A	Journal of American Chemical Society, Volume 113, issued 1991, K.M. Shokat et al, "Redirecting the Immune Response: Ligand-Mediated Immunogenicity", pages 1861-1862.	11-19
A	SCIENCE, Volume 246, issued 13 October 1989, N. Sharon et al, "Lectins as Cell Recognition Molecules", pages 227-234.	11-19
A	Proceedings of the National Academy of Sciences, Volume 85, issued May 1988, J. Badger et al, "Structural analysis of a series of antiviral agents complexed with human rhinovirus 14", pages 3304-3308.	11-19
A	Biochemistry, Volume 28, issued 1989, N.K. Sauter et al, "Hemagglutinins from Two Influenza Virus Variants Bind to Sialic Acid Derivatives with Millimolar Dissociation Constants: A 55-MHz Proton Nuclear Magnetic Resonance Study", pages 8388-8396.	11-19
A	JOURNAL OF AMERICAN CHEMICAL SOCIETY, Volume 113, issued 1991, A. Spaltenstein et al, "Polyacrylamides Bearing Pendant α -Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus", pages 686-687.	11-19
A	Tetrahedron Letters, Volume 31, No. 13, issued 1990, (LONDON, GB), D. Crich et al, "SYNTHESIS OF 2-DEOXY- β -D-PYRANOSIDES BY DIASTEREOSELECTIVE HYDROGEN ATOM TRANSFER", pages 1897-1900.	11-19
A	JOURNAL OF ORGANIC CHEMISTRY, Volume 52, issued 1987, F. Nicotra et al, "Stereoselective Access to α - and β -D-Fructofuranosyl C-Glycosides", pages 5627-5630.	11-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03065

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/450; 435/7.2, 7.22, 7.32, 7.37; 514/23, 53, 54, 61, 63, 837, 888; 536/4.1, 17:2